Organization
Institut Català D'Oncologia
9 abstracts
Abstract
Second-line endocrine therapy (ET) with or without palbociclib (P) maintenance in patients (pts) with hormone receptor-positive (HR[+])/human epidermal growth factor receptor 2-negative (HER2[-]) advanced breast cancer (ABC): PALMIRA trial.Org: Kent Oncology Centre, Istituto Europeo Oncologico, Hôpital Européen Georges Pompidou, Medica Scientia Innovation Research (MEDSIR), Pangaea Oncology,
Abstract
Epcoritamab + R2 regimen and responses in high-risk follicular lymphoma, regardless of POD24 status.Org: Dana-Farber Cancer Institute, Institut Català D'Oncologia, Leiden University Medical Center, Rigshospitalet, Copenhagen University Hospital, Ronald Reagan University of California Los Angeles Medical Center,
Abstract
Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Patient-reported outcomes (PROs) from the TROPION-Breast01 study.Org: Institut Català D'Oncologia, IDIBELL, Seoul National University Hospital, Cancer Research Institute, Aichi Cancer Center Hospital,
Abstract
Primary results from PATRICIA cohort C (SOLTI-1303), a randomized phase II study evaluating palbociclib with trastuzumab and endocrine therapy in pretreated HER2-positive and PAM50 luminal advanced breast cancer.Org: SOLTI Cancer Research Group, Department of Medical Oncology, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute, Vall d’Hebron Institute of Oncology,
Abstract
Fulvestrant with or without the cyclin-dependent kinase 7 (CDK7) inhibitor samuraciclib in advanced hormone receptor positive (HR+) breast cancer after CDK4/6 inhibition: Phase II SUMIT-BC study.Org: Institut Català D'Oncologia, IDIBELL, L’Hospitalet, Hospital Universitario Marques de Valdecilla, Hospital Vithas Málaga,
Abstract
Bromodomain and extra-terminal (BET) inhibitor INCB057643 (LIMBER-103) in patients (pts) with relapsed or refractory myelofibrosis (R/R MF) and other advanced myeloid neoplasms: A phase 1 study.Org: Sylvester Cancer Center, Emory University School of Medicine, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Hospital Germans Trias i Pujol, Institut Català D'Oncologia,
Abstract
Effect of follow-up time on the ability of subcutaneous epcoritamab to induce deep and durable complete remissions in patients with relapsed/refractory large B-cell lymphoma: Updated results from the pivotal EPCORE NHL-1 trial.Org: University of Michigan Comprehensive Cancer Center, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, MSC National Research Institute of Oncology, Kraków, Poland, Sir Charles Gairdner Hospital,
Abstract
Five-year subgroup analysis of tafasitamab + lenalidomide from the phase II L-MIND study in patients with relapsed or refractory diffuse large B-cell lymphoma.Org: Vall d’Hebron Institute of Oncology (VHIO), Ludwig-Maximilians-University Hospital, University of Eastern Piedmont, Institut Català D'Oncologia, IDIBELL,
Abstract
Safety analysis of lurbinectedin versus topotecan in elderly patients.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Fondazione IRCCS - Istituto Nazionale dei Tumori, Fondazione Policlinico Gemelli IRCCS, Hospital Universitario Virgen de la Victoria, Institut Gustave Roussy,